|
HUE062616T2
(hu)
|
2011-09-08 |
2023-11-28 |
Sage Therapeutics Inc |
Neuroaktív szteroidok, készítmények és alkalmazásaik
|
|
EP4717314A2
(en)
|
2011-10-14 |
2026-04-01 |
Sage Therapeutics, LLC |
3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
|
|
SG10201606063RA
(en)
|
2012-01-23 |
2016-09-29 |
Sage Therapeutics Inc |
Neuroactive steroid formulations and methods of treating cns disorders
|
|
RS62761B1
(sr)
|
2012-08-21 |
2022-01-31 |
Sage Therapeutics Inc |
Alopregnanolon za lečenje refraktornog epileptičkog statusa
|
|
US20150313915A1
(en)
|
2012-11-30 |
2015-11-05 |
The Regents Of The University Of California |
Anticonvulsant activity of steroids
|
|
FI3932932T3
(fi)
|
2013-03-13 |
2025-10-15 |
Sage Therapeutics Inc |
Neuroaktiivisia steroideja ja niiden käyttömenetelmiä
|
|
WO2014169836A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor neuroactive steroids and methods of use thereof
|
|
CN117304245A
(zh)
|
2013-04-17 |
2023-12-29 |
萨奇治疗股份有限公司 |
刺激神经活性的19-去甲类固醇及其使用方法
|
|
SMT202100509T1
(it)
|
2013-04-17 |
2021-11-12 |
Sage Therapeutics Inc |
Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
|
|
US9725481B2
(en)
|
2013-04-17 |
2017-08-08 |
Sage Therapeutics, Inc. |
19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
|
|
CA2918735C
(en)
|
2013-07-19 |
2023-08-01 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
CN105579043B
(zh)
|
2013-08-23 |
2021-09-14 |
萨奇治疗股份有限公司 |
神经活性类固醇、组合物和其用途
|
|
JP6628745B2
(ja)
|
2014-06-18 |
2020-01-15 |
セージ セラピューティクス， インコーポレイテッド |
オキシステロールおよびその使用方法
|
|
US10246482B2
(en)
|
2014-06-18 |
2019-04-02 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
MA40498A
(fr)
|
2014-09-02 |
2021-05-19 |
Texas A & M Univ Sys |
Méthode de traitement de l'intoxication par organophosphates
|
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
|
MY190408A
(en)
|
2014-10-16 |
2022-04-21 |
Sage Therapeutics Inc |
Compositions and methods for treating cns disorders
|
|
US20170233433A1
(en)
|
2014-10-16 |
2017-08-17 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
WO2016082789A1
(en)
|
2014-11-27 |
2016-06-02 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
LT3250210T
(lt)
*
|
2015-01-26 |
2021-04-12 |
Sage Therapeutics, Inc. |
Kompozicijos ir būdai, skirti gydyti cns sutrikimus
|
|
DK3258939T3
(da)
|
2015-02-20 |
2022-12-12 |
Sage Therapeutics Inc |
Neuroaktive steroider, sammensætninger og anvendelser heraf
|
|
WO2017007832A1
(en)
|
2015-07-06 |
2017-01-12 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
|
PT3319611T
(pt)
|
2015-07-06 |
2021-04-22 |
Sage Therapeutics Inc |
Oxisteróis e métodos de utilização dos mesmos
|
|
DK3812392T3
(da)
|
2015-07-06 |
2025-07-21 |
Sage Therapeutics Inc |
Oxysteroler og fremgangsmåder til anvendelse deraf
|
|
PH12018501923B1
(en)
|
2016-03-08 |
2024-06-28 |
Sage Therapeutics Inc |
Neuroactive steroids, compositions, and uses thereof
|
|
ES2921010T3
(es)
|
2016-04-01 |
2022-08-16 |
Sage Therapeutics Inc |
Oxisteroles y procedimientos de uso de los mismos
|
|
WO2017193046A1
(en)
|
2016-05-06 |
2017-11-09 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
|
WO2018009867A1
(en)
|
2016-07-07 |
2018-01-11 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
|
CA3030420C
(en)
|
2016-07-11 |
2025-11-18 |
Sage Therapeutics, Inc. |
C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
|
|
WO2018013613A1
(en)
*
|
2016-07-11 |
2018-01-18 |
Sage Therapeutics, Inc. |
C17, c20, and c21 substituted neuroactive steroids and their methods of use
|
|
TW202604538A
(zh)
|
2016-08-23 |
2026-02-01 |
美商賽吉醫療公司 |
結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
|
|
MA46351A
(fr)
|
2016-09-30 |
2021-06-02 |
Sage Therapeutics Inc |
Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
|
|
KR102521573B1
(ko)
|
2016-10-18 |
2023-04-14 |
세이지 테라퓨틱스, 인크. |
옥시스테롤 및 그의 사용 방법
|
|
DK3529257T3
(da)
|
2016-10-18 |
2023-08-07 |
Sage Therapeutics Inc |
Oxysteroler og fremgangsmåder til anvendelse deraf
|
|
US12139508B2
(en)
*
|
2018-02-11 |
2024-11-12 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Steroid derivative regulators, method for preparing the same, and uses thereof
|
|
MX2020008182A
(es)
*
|
2018-02-11 |
2020-09-22 |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Reguladores de derivados esteroides, metodo para prepararlos y usos de los mismos.
|
|
JP7670626B2
(ja)
|
2019-05-31 |
2025-04-30 |
セージ セラピューティクス， インコーポレイテッド |
神経刺激性ステロイド及びその組成物
|
|
AU2021238346A1
(en)
|
2020-03-18 |
2022-09-29 |
Sage Therapeutics, Inc. |
Neuroactive steroids and their methods of use
|
|
US12215126B2
(en)
*
|
2020-05-21 |
2025-02-04 |
Brigham Young University |
Cationic steroidal antimicrobial compounds with endogenous groups
|
|
WO2023060067A1
(en)
|
2021-10-04 |
2023-04-13 |
Marinus Pharmaceuticals, Inc. |
Amorphous solid dispersion ganaxolone formulation
|